A
wide range in screening rates for diabetic retinopathy by dilated ophthalmic examination has been reported in studies over the last decade (1) (2) (3) (4) . Comparisons of these rates should take into account the measure used to assess the condition (i.e., screened versus unscreened). Examples of measures include self-report by the individual, claims data for the service, or medical record abstraction of the desired information. Because goals for improvement of diabetes care (5) are based on studies using these reported rates, the sources of these data must be considered and described. Selfreport by an individual relies on memory, correct discernment of a dilated versus undilated exam, and accurate identification of the screening behavior within the time frame in question. Claims data, on the other hand, can overestimate the rate of dilated exams under the code for a comprehensive ophthalmic examination. Furthermore, depending on the patient's health care coverage plan, the retinopathy screening may be a service that does not require a separate claim. Finally, abstraction of medical records may be a sensitive measure for a dilated ophthalmic examination; however, its specificity is dependent on a record system that captures and organizes the medical reports for retrieval and evaluation.
A recently published study by Basch et al. (6) reported that a telephone-based health education intervention was associated with a doubling in the rate of dilated ophthalmic examinations (54.7% screened in the intervention group vs. 27.3% in the standard care group) in a sample of African-American adults with diabetes. The main outcome for that randomized controlled trial was documentation from the medical record of receipt of a dilated eye examination. In addition, staff conducted telephone interviews to ascertain self-report of a dilated eye examination. The cross-classification of documented and self-reported screening status from that study is presented here in order to describe the accuracy (7) of self-report of a dilated eye examination.
Eligibility for the randomized trial specified that participants had not had a dilated eye examination in the previous 14 months. The current standard of diabetes care is for an annual dilated eye examination (8). A total of 280 AfricanAmericans with diabetes from five New York City metropolitan area medical centers consented to be randomized and completed the study. Documentation of a dilated eye examination consisted of medical record abstraction by an auditor masked to group assignment. If in the telephone interview the subject reported having gone to an outside eye care provider and signed a medical release, then a form for provider documentation of the date of the most recent dilated eye examination was obtained. Because the documented outcome from the medical record would have superceded the patients' selfreport as the primary outcome for this study, completion of the telephone interview was not a prerequisite for inclusion in the published report. There was no self-report for 32 subjects because of the staff's inability to contact the subjects by telephone, even after repeated attempts. Each of the remaining 248 subjects included in this current report had both self-report and accessible medical record documentation for eye examination status. Inaccessible medical records for seven subjects (three intervention subjects and four control subjects) were conservatively treated as a negative for the dichotomous categories of screened versus unscreened.
The telephone interviewer, masked to group assignment, asked, "When was the last time you had an eye exam in which the pupils were dilated?" Response options were: "less than 1 month," "1-12 months," "13-24 months," "more than 2 years," and "never." We allowed plus or minus 1 month for error in recall. Thus, if a person reported having an exam in the past 1-12 months, and documentation indicated an exam 13 months ago, the self-report was considered verified. Similarly, the self-report was allowed to underestimate the time since last exam.
Rates of self-reported and documented dilated eye examinations for the entire sample (n ϭ 248) and for the intervention (n ϭ 119) and control (n ϭ 129) groups separately are as follows: selfreport was 58.5% for total sample, with 75.6 vs. 42.6% for intervention and control groups, respectively; documentation of exam was 44.0% for total sample, with 60.5 and 28.7%, respectively, for intervention and control groups. The apparent overestimation due to self-report was 33% in the total sample (58.5 vs. 44%), 48% in the control group (42.6 vs. 28.7%), and 25% in the intervention group (75.6 vs. 60.5%). The sensitivity of self-report for the total sample was 94.5, with intervention subjects showing greater sensitivity in self-report. Specificity overall was 69.8, with intervention subjects at 55.3 and control subjects at 77.2.
Objective 5-13 of Healthy People 2010 (5) is to increase the proportion of adults with diabetes who have an annual dilated eye examination from a 2000 baseline of 47% to a goal of 75%. The baseline was derived from self-report data. The National Health Interview Survey (NHIS) rate for African-Americans was 43%, which is virtually the same as the self-report data for the sample of African-Americans assigned to the control group, where the overestimation compared with documentation was by 48% (5).
These data indicate that self-report of a dilated ophthalmic exam and the documentation from the medical record or provider confirmatory letter are not in complete agreement. In fact, the intervention group had much less difference between the two measures than the control group. This difference could be because of a greater awareness of what constitutes a dilated eye examination, a result of the telephone-based health education and the brief behavioral counseling to improve retinopathy screening rates. Thus, accuracy of self-report data may be improved with greater patient education about what constitutes a dilated eye examination.
Ascertaining the true condition of screened versus unscreened for each subject was beyond the scope of this study and is a limitation of this report. It is possible that a subject's self-report of having had a dilated eye examination was indeed factual, but medical records were misfiled or incomplete; the great majority (Ͼ90%) of subjects in this report, however, re-ceived eye care from medical centers using a shared medical record for individuals among clinics. There is not an alternative gold standard measure for receipt of a dilated eye examination, absent the observation of the event. However, more advanced databases and electronic medical records should improve the accuracy of documentation in the near future, and this, in turn, will improve the benchmarking for retinopathy screening as a standard of diabetes care.
H
uman placental lactogen is higher in twin pregnancies than singleton pregnancies. Theoretically, this should increase insulin resistance and risk for gestational diabetes mellitus (GDM) (1). However, twin pregnancy has been found to be associated with a higher incidence of GDM in some studies (2,3) but not others (4,5). Polynesians have a high incidence of GDM (6), and we have investigated whether, in our multiethnic population, twin pregnancies are associated with a greater risk of GDM.
Locally, a universal screening policy using a nonfasting 50-g glucose challenge test (GCT) at 24 -28 weeks is advocated (6), and if the fasting glucose is Ն5.5 mmol/l and/or the 2-h post-oral glucose tolerance test (OGTT) 75-g load is Ն9.0 mmol/l, GDM is diagnosed (7). If a suspicion of GDM occurs (e.g., previous GDM or evidence of macrosomia), then direct referral to OGTT can occur. All women with twin pregnancies are managed within specialist antenatal services. This study was approved as an audit by the hospital management.
The methods have been previously described (6). Data relating to GDM and twin pregnancies were manually extracted from the medical records from all 5,462 deliveries in South Auckland Hospitals with discharges between 1 March 1994 and 28 February 1995. A total of 509 (9.3%) records were not found, and 14 women had known diabetes. Data are shown as the means Ϯ SD for twins versus singletons and are compared using ANOVA. Adjustment for age, weight, and parity was undertaken using ANCOVA. Parity is shown as median (interquartile range) and compared using the MannWhitney test. Proportions (n) were compared using the 2 test ( Data are means Ϯ SD, %, median (interquartile range), means Ϯ SD (n), % (n), and % (n/n). [2, 473] , P Ͻ 0.001), had a higher 1-h glucose challenge results (6.6 Ϯ 1.3 vs. 6.0 Ϯ 1.5; P ϭ 0.004 before age, weight, and parity adjustment and P ϭ 0.022 after), and were nonsignificantly more likely to have a positive screen on GCT (17.9% [7] vs. 12.6% [301], P ϭ 0.319) and GDM on OGTT after a positive GCT (50.0% [2/4] vs. 28.3% [66/ 233], P ϭ 0.342) than women with a singleton pregnancy, but numbers were small. Overall incidences of GDM were 11.9 and 5.1% (P ϭ 0.051).
Our data confirm that twin pregnancies are associated with greater risk of GDM with relative hyperglycemia. Unfortunately, the numbers of women with a twin pregnancy and an OGTT were too few to show a significantly higher incidence of GDM overall. The greater screening for GDM among women with twin pregnancies should have reduced the difference in GDM risk between the two groups, with the likely lower threshold for screening for GDM in these women (although closed unit versus shared care practice could be a further explanation). It was unfortunate that there were insufficient numbers to look at the risk of GDM within ethnic groups, but the groups were well matched for this. These data support the hypothesis that twin pregnancies are more prone to GDM. If so, women with twin pregnancies should be tested for GDM not only at 24 -28 weeks but also later on in pregnancy. • Additional pieces of supporting evidence were the absence of hyperexpression of major histocompatibility complex class I molecules in islets and the presence of lymphocyte infiltration in exocrine pancreatic tissue without insulitis in biopsy specimens. Consequently, high serum amylase levels were the primary characteristics of patients with fulminant type 1 diabetes. However, the hypothesis mentioned above has not been universally accepted (3) . We report a case of fulminant type 1 diabetes in a patient who had a normal level of serum amylase at the time of diagnosis along with increased rheumatoid factor and thyroid-stimulating hormone (TSH) receptor antibody levels.
DAVID SIMMONS, FRACP
A 22-year-old woman was admitted to our hospital with diabetic ketoacidosis. She suffered from a sore throat and headache 7 days before admission. Nausea, vomiting, and slight fever started 2 days before admission. She visited the emergency room with epigastric pain and thirst and was found to have a high glucose level. She was transferred to our hospital the next day for admission.
The patient was comatose when she arrived. Her plasma glucose level was 59.6 mmol/l. Her HbA 1c was 5.3%, within normal range. Urinary ketone was strongly positive. Arterial pH was 6.922, and bicarbonate was 1.9 mmol/l. Serum and urinary C-peptide levels were low, 0.24 ng/ml and 5.6 g/day, respectively. She had no diabetes-related antibodies (GAD antibody, tyrosine phosphataselike protein [IA-2] antibody, islet cell antibody, or insulin autoantibody). These findings were consistent with the characteristics of fulminant type 1 diabetes.
The patient's serum amylase level was 71 IU/l in the emergency room and 135 IU/l at the time of her admission to our hospital, but it rose to 761 IU/l the next day. The serum levels of other exocrine pancreatic enzymes lipase and trypsin also rose, although the levels of these two enzymes were not measured on the day of admission. These findings suggested that injury to exocrine pancreatic tissue indeed occurred in this subject. However, we considered this injury to be secondary, based on the initially normal amylase level and its subsequent rise.
This patient had HLA-DRB1*0405/ *0405, DQA1*0303/*0303, DQB1*0405/ *0405, the haplotype associated with type 1 diabetes in Japanese people. Furthermore, her immunological examinations after ad-mission showed elevated rheumatoid factor and the temporal presence of TSH receptor antibody. These findings suggested that her disease had the immunogenetic characteristics of an autoimmune disease but not against the endocrine pancreas.
Unlike previous cases of fulminant type 1 diabetes (4), this case was characterized by a late increase in serum amylase level and autoimmune characteristics. Therefore, although fulminant type 1 diabetes has been clinically identified, its etiology remains in question. 2) . Predominantly based on studies in type 2 diabetic populations, it has been suggested that microalbuminuria is an early indicator of atherosclerosis (3). Whether, in nondiabetic subjects, microalbuminuria is an independent indicator of subclinical atherosclerosis or merely a reflection of the increased prevalence of cardiovascular risk factors remains a matter of debate (4). Therefore, in the present study, we investigated the relation between urinary albumin excretion (UAE) and intima-media thickness (IMT) in both a nondiabetic and a type 2 diabetic population.
SHINJI SAKAUE
Subjects were recruited on the basis of reproducible microalbuminuria (UAE once Ͼ10 mg/l in an early morning spot urine and at least once 15-300 mg/24 h in 2 ϫ 24 h urine samples). The IMT was measured at the posterior wall of the left common carotid artery using radio frequency signal analysis obtained by Mmode ultrasonography. Type 2 diabetes was defined as currently using antidiabetic drugs or a fasting plasma glucose exceeding 6.1 mmol/l. A total of 481 men and 257 women with a mean age of 50 years were included. Adjusted for age and sex, UAE was related to diastolic and systolic blood pressure as well as BMI in diabetic (n ϭ 57) and nondiabetic subjects (n ϭ 681). All relations between UAE and these variables were stronger in the type 2 diabetic population. In both diabetic and nondiabetic subjects, a positive relation was present between UAE and IMT ( Table  1) . In nondiabetic subjects, this relation could no longer be demonstrated after correction for age, sex, and classical cardiovascular risk indicators. In contrast, in type 2 diabetes patients, the relation between UAE and IMT remained highly significant after risk factor correction.
This study shows that UAE is strongly related to subclinical atherosclerosis (assessed as IMT) in type 2 diabetes patients, whereas in healthy volunteers, the relation between UAE and IMT is predominantly a consequence of a clustering of cardiovascular risk indicators. The latter observation implies that if microalbuminuria proves to be an independent risk indicator for cardiovascular disease in the nondiabetic population, this is due to mechanisms other than enhanced atherosclerosis progression per se. 
Correlation of Serum Leptin Levels With Insulin Sensitivity in Patients With Chronic Hepatitis-C Infection

D
iabetes is a less-recognized association of hepatitis-C virus (HCV) infection, although several recent studies provide data linking HCV infection and diabetes (1-5). To investigate whether patients with chronic HCV infection without evidence of cirrhosis have an increased risk of diabetes, we conducted a case-control study in 44 consecutive eligible patients with HCV infection and no clinical or histological evidence of cirrhosis and in 20 control subjects without liver disease who were matched by age, sex, and BMI. All 44 patients with chronic HCV infection had biochemical evidence of ongoing inflamation with elevated alanine aminotransferase activity and histologic confirmation. There was no evidence of decompensated liver disease. The fasting serum insulin levels were significiantly elevated in patients with chronic HCV infection compared with control subjects (22.5 Ϯ 7.9 vs. 9.0 Ϯ 2.8, P Ͻ 0.001). Serum leptin levels were also significiantly elevated in patients with chronic HCV infection compared with control subjects (11.8 Ϯ 4.3 vs. 6.0 Ϯ 3.6, P Ͻ 0.001). Fasting serum leptin and insulin levels and HOMAestimated insulin sensitivity were correlated in the whole group. There was a significant positive correlation between serum leptin and insulin (r ϭ 0.43, P Ͻ 0,001) and between leptin and HOMAestimated insulin sensitivity (r ϭ 0.42, P Ͻ 0,01). Mehta et al. (5) reported the analysis of HCV infection and type 2 diabetes in the Third National Health and Nutrition Examination Survey. They reported that patients with HCV infection were more than three times as likely to have type 2 diabetes than those without HCV infection.
In conclusion, our study results suggest that HCV infection may serve as an additional risk factor for the development of type 2 diabetes due to insulin resistance and hyperleptinemia. Investigators from many disciplines will need to prospectively characterize the temporal sequence of HCV infection and type 2 diabetes, define the relationship with serious liver disease, and explicate the biological mechanisms. from Mexico City, Mexico. This difference was not accounted for by the potential mediating factors examined (BMI; waist circumference; fasting and 2-h post-glucose load insulin and glucose; fasting triglycerides and HDL cholesterol; and percentage of impaired glucose tolerance, impaired fasting glucose, or hypertension).
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However, in our opinion, an important consideration is missing: the possible role of reduced insulin sensitivity in the high incidence of type 2 diabetes in San Antonio. Indeed, analysis of the data shown in Table 2 of the paper by Burke et al. indicates that both men and women who were residents in San Antonio had statistically significant higher 2-h glucose and 2-h insulin levels compared with men and women who were residents in Mexico City. The simultaneous increase in insulin and glucose levels suggests the occurrence of reduced insulin sensitivity.
Recently, we published a method that allows the quantitative measurement of insulin sensitivity from the insulin and glucose levels recorded at 0, 1, and 2 h during an oral glucose tolerance test (OGTT), or even (with minimal loss of sensitivity) from data recorded only at 0 and 2 h (2-4). Because the values of insulin and glucose at 0 h (i.e., in the fasting state) and at 2 h during OGTT are given in the article by Burke et al., it was possible for us to calculate insulin sensitivity. Our method is based on the following formula: ISI(gly) ϭ 2/[(INSp ϫ GLYp) ϩ 1], where ISI(gly) indicates the insulin sensitivity index toward glycemia [our method also allows the measurement of insulin sensitivity toward blood free fatty acids (FFAs), or ISI(ffa)] and INSp and GLYp indicate insulinemic and glycemic areas, respectively, during OGTT for the person studied. Because this test is based on the "areas" during OGTT, it can be indicated as ISI(gly)-a. By using basal levels, instead of areas, we can measure the insulin sensitivity in the basal state, or ISI(gly)-b. Both the basal levels and areas are expressed by taking the "mean normal value" as 1 (i.e., by dividing the observed value by the mean normal value). In normal subjects, ISI(gly) is always ϳ1, with maximal variations among patients comprised between 0 and 2. ISI(gly), as well as the insulin sensitivity index toward blood FFAs, can be easily calculated through a computer program that is freely downloadable from the following website:
http://users.iol.it/francesco.belfiore/ index.htm.
As just mentioned, to measure insulin sensitivity with our method, the mean normal values of basal levels and areas of insulin and glucose are required. Because Burke et al. did not include a "normal" group in their study, we used as mean normal values for insulin and glucose those values reported in Table 1 of a previous article by the same authors (5); the values were obtained from 870 individuals of both sexes. Note, however, that the use of different mean normal values would equally affect the ISI(gly) values in both groups (Mexico City and San Antonio residents) and therefore would not alter the difference between them. Results of our analysis are shown here in Table 1 .
These values of insulin sensitivity obtained with our index are derived from the mean values (and not from individual values) of insulin and glucose reported in Table 1 of the article by Burke et al. (1) . Therefore, they cannot be statistically evaluated. However, because the reduced values of ISI(gly)-a that we found in the San Antonio population were derived from the "areas" that showed statistically significant difference between the two populations, these reduced values should be statistically significant. On the other hand, the ISI(gly)-b is derived from basal values of insulin and glucose, which changed in opposite directions in the two populations, thus annulling each others statistical significance.
Thus, because the value of ISI(gly) in normal subjects is always equal to 1, both of the populations studied have reduced insulin sensitivity. However, compared with Mexico City residents, the San Antonio population shows a more pronounced reduction in insulin sensitivity deduced from the areas during OGTT, i.e., during the absorption period (characterized by high insulin and glucose levels), but not in the basal state. This is true for both men and women. This observation, which in turn may depend on several factors, may contribute to explain the different incidence of diabetes between the two populations. (1) for their interesting questions regarding our study (2) . We agree that lower insulin sensitivity in the San Antonio, Texas pop- Table 1 , ISI-a was significantly higher in Mexico City, whereas ISI-b was not, thus confirming the calculations of Belfiore and Iannello. As noted by Belfiore and Iannello, these associations, which parallel the fasting and 2-h insulin values in Mexico City, could reflect impaired insulin secretion rather than enhanced insulin sensitivity. Controlling for either ISI-a or -b did not attenuate the odds ratios reflecting the excess incidence of diabetes in San Antonio (Table 2) . Thus, these indexes of insulin sensitivity do not account for the difference in incidence between the two cities. However, because these indexes may not be perfectly correlated with insulin sensitivity measured by a more definitive method, e.g., the euglycemic clamp, we do not dispute that differences in insulin sensitivity may account for part of the incidence difference between the two cities. • 
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On Methods and Materials
Response to Parretti et al.
P
arretti et al. (1) were very meticulous in assuring that their subjects had similar demographics and were glucose tolerant, healthy, and of similar gestational age. Of note is their finding of a mean fasting glucose value of 56.2 mg/dl and mean 24-h glucose values of 74.7 mg/ dl. These results are substantially lower than those found by previous investigators who reported fasting plasma glucose concentrations between 78 and 80 mg/dl (2-4) and 24-h mean glucose concentrations between 85 and 96 mg/dl (2,5,6). Before one accepts the results of the study by Parretti et al. as representative of those of nondiabetic women in the third trimester, it seems appropriate to question whether differences in methodology might explain these seeming inconsistencies.
The meter (Accutrend ␣) that was used in their study is calibrated to give results equivalent to whole blood, not plasma glucose. Because the concentration of glucose in plasma is greater than that of red cells, the higher the hematocrit, the higher the plasma glucose corresponding to the same patient's wholeblood glucose concentration (7). For example, assuming a hematocrit of 35%, the plasma glucose equivalent of the fasting and overall daily mean glucose reported in the study were 65.4 and 87.0 mg/dl, respectively. Such a conversion brings the mean glucose concentrations reported by the authors into closer proximity with those reported by others.
In contrast with previous studies, the authors had patients check and report their own glucose level. The protocol required that each subject report a total of 15 blood glucose tests taken around the clock for 1 day every 2 weeks from 28 to 38 weeks. The Accutrend ␣ has a memory capacity for only nine results and cannot be downloaded to a computer. Thus, it seems likely that the patients' results were self reported and not transcribed directly from the meter. Unless the investigators verified these results, either by direct observation or by running duplicate saved samples independently in the laboratory, the credibility of these results may legitimately be called into question. There were no significant city-risk factor interactions. Hopefully these comments will aid in the interpretation and application of the findings of this unique study. a combination of different elements is effective in improving diabetes care, but which specific combination is the most effective is not clear. The addition of patient education or a nurse to multifaceted interventions aimed at facilitating structured care seems to be of important additional value in improving patient outcomes as well as the process of care (3).
